UK centre for asbestos-related medtech R&D "progressing rapidly"
This article was originally published in Clinica
The establishment in the UK of a National Centre for Asbestos-Related Diseases (NCARD) is "moving forward" and "progressing quite rapidly", MPs have been told. The issue was on the agenda of yesterday evening's meeting of the Asbestos Sub-Committee of the All-Party Parliamentary Group on Occupational Safety and Health. Chairman Michael Clapham MP told the committee that a leading UK consultant acting as adviser to the committee had held a number of meetings on the project and "is quite satisfied with the progress being made".
You may also be interested in...
Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.